Prelude Therapeutics (PRLD) announced the publication of two abstracts with preclinical data on the Company’s JAK2V617F mutant selective inhibitors and CALR-targeted degrader antibody conjugates, DACs, discovery program, both accepted for oral presentation at the American Society of Hematology, ASH, 67th Annual Meeting taking place in Orlando, FL December 6-9, 2025. The abstracts can be found on the ASH 2025 website ASH Annual Meeting & Exposition.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRLD:
- Prelude Therapeutics Advances with PRT7732 in Targeted Cancer Therapy
- Prelude Therapeutics Appoints Katina Dorton to Board
- Prelude Therapeutics appoints Katina Dorton to board of directors
- Prelude Therapeutics: Promising SMARCA2-Targeted Degraders and Positive Outlook Support Buy Rating
- Prelude Therapeutics Regains Nasdaq Compliance